NEWPORT BEACH, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in the 10 th Annual SVB Leerink Global Healthcare Conference.
Event: | 10 th Annual SVB Leerink Global Healthcare Conference | ||
Format: | Fireside Chat & 1x1 Meetings | ||
Date: | Wednesday, February 24, 2021 | ||
Time: | 1:00pm – 1:30pm ET | ||
Location: | Evolus Live Fireside Chat |
An audio webcast of Evolus’ fireside chat will be available on the investor relations section of Evolus’ website at investors.evolus.com . Replays of the webcasts will be available for 90 days after the date of the presentation.
About Evolus, Inc.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau ® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure ™ technology. Jeuveau ® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: www.evolus.com .
Jeuveau ® is a registered trademark of Evolus, Inc.
Hi-Pure ™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Evolus, Inc. Contacts:
Investor Contact:
Ashwin Agarwal, Evolus, Inc.
Vice President, Finance, Investor Relations & Treasury
Tel: +1-949-284-4559
Email: IR@Evolus.com
Media Contact:
Crystal Muilenburg, Evolus, Inc.
Vice President, Corporate Communications & Public Relations
Tel: +1-949-284-4506
Email: media@evolus.com